Clinical TopicsWeb Exclusives
fda opioid withdrawal symptom

FDA permits marketing of device to help reduce opioid withdrawal symptoms

Share

On Nov. 15, the U.S. Food and Drug Administration (FDA) granted a new indication to an electric stimulation device (NSS-2 Bridge) for use in helping to reduce the symptoms of opioid withdrawal. Read more via Fda.gov.

Test Your Knowledge

Which type of skin cancer is the deadliest, despite accounting for only 1% of all skin cancer cases?

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • This field is hidden when viewing the form

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts